Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Veronica Davis

Internal Medicine Wesley Chapel, FL Doctor of Osteopathy

NPI 1770743015 CMS profile 216061

2352 Bruce B Downs Blvd Ste 301, Wesley Chapel, FL 33544

Open in the dashboard

General payments

$6,668

432 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Veronica Davis of Wesley Chapel, FL is reported in the CMS Open Payments database as having received $6,668 across 432 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,096 57
2024 General $990 54
2023 General $1,053 64
2022 General $978 62
2021 General $860 61
2020 General $736 56
2019 General $956 78

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Veronica Davis
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Veronica Davis were reported at $1,096. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Veronica Davis Internal Medicine median Middle half National median
2019 $956 $159 $48–$570 $163
2020 $736 $119 $33–$402 $114
2021 $860 $135 $37–$521 $132
2022 $978 $141 $42–$496 $149
2023 $1,053 $149 $45–$519 $160
2024 $990 $154 $47–$537 $164
2025 $1,096 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $2,848 216 payments
  2. AstraZeneca Pharmaceuticals LP $972 59 payments
  3. Lilly USA, LLC $467 28 payments
  4. AbbVie, Inc. $333 19 payments
  5. Abbott Laboratories $301 18 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $284 13 payments
  7. Dexcom, Inc. $161 9 payments
  8. Sanofi-Aventis U.S. LLC $145 7 payments
  9. Pfizer Inc. $105 6 payments
  10. GlaxoSmithKline, LLC. $101 6 payments
  11. Other $951 51 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,647 430 payments
  2. Education $21 2 payments
Products named General payments · program years 2019–2025
  1. Ozempic $1,992 157 payments
  2. RYBELSUS $1,514 112 payments
  3. Wegovy $726 44 payments
  4. FARXIGA $647 41 payments
  5. JARDIANCE $256 11 payments
  6. FreeStyle Libre 3 $254 15 payments
  7. UBRELVY $232 14 payments
  8. AIRSUPRA $229 12 payments
  9. MOUNJARO $216 12 payments
  10. QULIPTA $173 9 payments
  11. Other $2,990 180 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 93 drugs

Part D claims

3,333

Median for Internal Medicine: 777

Drug cost

$526,171

Median for Internal Medicine: $73,373

Branded share of claims

23.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 216 $290,783
Ozempic Semaglutide Brand 53 $62,265
Jardiance Empagliflozin Brand 35 $34,054
Rybelsus Semaglutide Brand 25 $25,224
Synjardy Empagliflozin/Metformin Hcl Brand 26 $18,061
Eliquis Apixaban Brand 13 $16,411
Repatha Sureclick Evolocumab Brand 13 $12,709
Myrbetriq Mirabegron Brand 16 $8,314
Belsomra Suvorexant Brand 13 $5,853
Duloxetine Hcl Generic 59 $4,150

The 10 drugs with the highest cost, of 93 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$62,505

Of which drugs: $14,741

Medicare patients

155

Average age 74

Services billed

918

103 women, 52 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Diabetes 38%
Ischemic heart disease 35%
Osteoporosis 28%
Chronic kidney disease 22%
Depression 20%
COPD 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 43 43 $12,513
Vaccine for influenza for injection into muscle 90662 Office 24 25 $1,996

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Wegovy
  • Novo Nordisk Inc $213
$213 — —
Ozempic
  • Novo Nordisk Inc $130
$130 53 —
RYBELSUS
  • Novo Nordisk Inc $111
$111 25 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $108
$108 — —
MOUNJARO
  • Lilly USA, LLC $64
$64 216 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

432 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record